Serum Contactin-1 in CIDP: A Cross-Sectional Study

Luuk Wieske, Lorena Martín-Aguilar, Janev Fehmi, Cinta Lleixà, Marleen J. A. Koel-Simmelink, Madhurima Chatterjee, Zoë van Lierop, Joep Killestein, Camiel Verhamme, Luis Querol, Simon Rinaldi, Charlotte E. Teunissen, Filip Eftimov

Research output: Contribution to journalArticleAcademicpeer-review


OBJECTIVE: To investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region. METHODS: Serum contactin-1 levels were measured in 187 patients with CIDP and 222 healthy controls. Paranodal antibodies were investigated in all patients. RESULTS: Serum contactin-1 levels were lower in patients (N = 41) with paranodal antibodies compared with patients (N = 146) without paranodal antibodies (p < 0.01) and showed good discrimination between these groups (area under the curve 0.84; 95% CI: 0.76-0.93). CONCLUSIONS: These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP. CLASSIFICATION OF EVIDENCE: This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%-85%) and a specificity of 97% (95% CI: 83%-100%).

Original languageEnglish
JournalNeurology(R) neuroimmunology & neuroinflammation
Issue number5
Publication statusPublished - 1 Jul 2021

Cite this